Location History:
- Daejeon, KR (2023)
- Seongnam-si, KR (2024)
Company Filing History:
4 out of 15 
1 out of 25 
1 out of 13 Years Active: 2023-2025
Title: Jiseon Yoo: Innovator in Bispecific Antibody Development
Introduction
Jiseon Yoo is a notable inventor based in Seongnam-si, South Korea, recognized for his significant contributions to the field of biopharmaceuticals. With a total of two patented innovations, his work focuses on advancing therapeutic options by developing bispecific antibodies targeting critical pathways in various diseases.
Latest Patents
Among Jiseon Yoo's most recent patents are two promising innovations in the realm of bispecific antibodies. The first, titled "Anti-PD-L1/anti-4-1BB bispecific antibodies and uses thereof," introduces an innovative bispecific antibody designed to effectively block the interactions between PD-L1 and its receptor PD-1, as well as between 4-1BB and its ligand. This invention is noteworthy for its potential to enhance immune response by having a high binding affinity to both PD-L1 and 4-1BB proteins.
The second patent, "Bispecific antibody to alpha-synuclein/insulin-like growth factor 1 receptor and use thereof," relates to a bi-specific antibody that selectively binds to alpha-synuclein and IGF1R. This invention is aimed at diagnosing and treating synucleinopathies linked to alpha-synuclein or its aggregates. Notably, the IGF1R component of the antibody enables it to navigate the blood-brain barrier, allowing the alpha-synuclein portion to exert its therapeutic effects within the brain. Furthermore, the design extends the half-life of the bispecific antibody, ensuring prolonged efficacy.
Career Highlights
Jiseon Yoo has had a distinguished career, having worked with prominent organizations such as Abl Bio Inc. and I-Mab Biopharma US Limited. These experiences have enriched his expertise and allowed him to contribute significantly to the field of therapeutic innovation.
Collaborations
Throughout his career, Jiseon Yoo has collaborated with several talented individuals. Notably, he has worked closely with Eunsil Sung and Hyejin Chung, the latter of whom contributes as a female colleague within his professional environment, fostering a collaborative atmosphere that encourages innovative developments.
Conclusion
Jiseon Yoo exemplifies the impact of innovation in the biopharmaceutical industry with his cutting-edge patents in bispecific antibodies. His contributions not only reflect his expertise but also highlight the importance of collaboration in achieving significant advancements in medical science. As he continues his work, the potential for his inventions to transform therapeutic practices and improve patient outcomes remains promising.